Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C N Sternberg, H Dumez, H Van Poppel, et al.
British Journal of Cancer
|
May 20, 2004
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
F M Wachters, H J M Groen, J G Maring, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
H Dumez, A Awada, M Piccart, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2006
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours
M J A de Jonge, H Dumez, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
G Daugaard, I Skoneczna, N Aass, et al.
Sarcoma
|
May 15, 2007
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients
G Huygh, Paul M J Clement, H Dumez, et al.
Acta Clinica Belgica
|
January 29, 2011
A case series of embryonal rhabdomyosarcoma of the head and neck in adults
J Wagemans, B Beuselinck, S Nuyts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)
S Stroobants, J Goeminne, M Seegers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter, H Dumez, I Judson, et al.
Anti-Cancer Drugs
|
August 13, 2002
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors
H Dumez, M Louwerens, A Pawinsky, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 20, 2009
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C N Sternberg, H Dumez, H Van Poppel, et al.
British Journal of Cancer
|
May 20, 2004
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
F M Wachters, H J M Groen, J G Maring, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 8, 2006
A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours
H Dumez, A Awada, M Piccart, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 4, 2006
Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours
M J A de Jonge, H Dumez, J Verweij, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 10, 2010
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974)
G Daugaard, I Skoneczna, N Aass, et al.
Sarcoma
|
May 15, 2007
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients
G Huygh, Paul M J Clement, H Dumez, et al.
Acta Clinica Belgica
|
January 29, 2011
A case series of embryonal rhabdomyosarcoma of the head and neck in adults
J Wagemans, B Beuselinck, S Nuyts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)
S Stroobants, J Goeminne, M Seegers, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 11, 2004
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group
M Debiec-Rychter, H Dumez, I Judson, et al.
Anti-Cancer Drugs
|
August 13, 2002
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors
H Dumez, M Louwerens, A Pawinsky, et al.
Page
of 3